4.19 -0.08 (-1.88%)
CADX
| Trade CADX now with |
|
Stock Details
Last Trade:4.19 Change:-0.08 (-1.88%) Prev Close:4.27 Open: 4.26 Days Range:4.07 – 4.32 52 Week Range: 3.41 - 10.00 Volume:393592 P/E: N/AEPS:-1.37
View AllRecent Alerts 02/09/12
Recent Alert on 11/28/11 at 9:12am
Canaccord Genuity Reiterates a 'Buy' on Cadence Pharma (CADX); Encouraging October Ofirmev RX Trends, Stronger Balance Sheet
Canaccord Genuity Reiterates a 'Buy' on Cadence Pharma (CADX); Encouraging October Ofirmev RX Trends, Stronger Balance Sheet
Canaccord Genuity reiterates a 'Buy' on Cadence Pharma (NASDAQ: CADX) price target cut $1 to $9. Canaccord analyst, Ritu Baral, said, "Lowering target to $9 on post-offering increase in share count. We think Ofirmev will ultimately be used as part... Read More
Recent Alert on 11/23/11 at 1:27pm
Wedbush Cuts Price Target on Cadence Pharma (CADX), Tweaks Estimates on OFIRMEV Vial Sales
Wedbush Cuts Price Target on Cadence Pharma (CADX), Tweaks Estimates on OFIRMEV Vial Sales
Recent Alert on 11/17/11 at 10:53am
UBS maintains a 'Neutral' on Cadence Pharma (CADX); Updated Thoughts on Secondary Offering
UBS maintains a 'Neutral' on Cadence Pharma (CADX); Updated Thoughts on Secondary Offering
View AllRecent Press Releases
Press Release on 02/06/12 at 5:00pm
Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
View AllRecent SEC Filings
View AllRecent Blog Posts
Blog Posts on 02/08/12 at 9:04am
Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall
Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall
Blog Posts on 01/24/12 at 3:32pm
Transcept's Intermezzo Has Significant Long Term Potential, But What About 2012?
Transcept's Intermezzo Has Significant Long Term Potential, But What About 2012?